Akeagen's CaMouse is an innovative genetically modified mouse strain engineered to generate heavy chain-only antibodies in vivo. Compared to existing antibody production platforms, our CaMouse technology offers superior VHH (nanobody) characteristics, including: Enhanced Affinity: Precisely engineered to produce antibody fragments with exceptional binding strength Increased Diversity: Capable of generating a wide range of unique antibody variants Improved Developability: Optimized for potential therapeutic and research applications For more detailed information about our groundbreaking CaMouse platform, please contact our team at info@akeagen.com.
About us
- Website
-
http://www.akeagen.com
External link for Akeagen, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held